Literature DB >> 11955656

Vasculitis due to gemcitabine.

A M C J Voorburg1, F T van Beek, P H Th J Slee, C A Seldenrijk, F M N H Schramel.   

Abstract

We report the first occurrence of gemcitabine-induced vasculitis. It concerns a 45-year-old man diagnosed with non-small lung cancer since 2 months. After the first cycle of chemotherapy, consisting of gemcitabine and cisplatin, he developed myalgia and swelling of arms and legs with impairment of movement. This re-occurred during the second cycle of chemotherapy. Further anemia, elevated ESR and increased creatininephosphokinase. A surgical biopsy showed leucocytoclastic vasculitis and necrosis of muscle tissue. The chemotherapy was stopped and the complaints disappeared and did not return.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955656     DOI: 10.1016/s0169-5002(01)00464-0

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  8 in total

1.  Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.

Authors:  Elena Pentsova; Anli Liu; Marc Rosenblum; Eileen O'Reilly; Xi Chen; Adília Hormigo
Journal:  J Neurooncol       Date:  2011-08-03       Impact factor: 4.130

2.  [Cerebral vasculitis associated with gemcitabine].

Authors:  P Schmorl; A Heer-Sonderhoff; R Vosshenrich; S Conrad
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

3.  Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.

Authors:  Toby A Eyre; Sarah Gooding; Ishita Patel; Niall Moore; Chris Hatton; Graham P Collins
Journal:  Int J Hematol       Date:  2014-03-02       Impact factor: 2.490

4.  The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis.

Authors:  B K Kleinschmidt-DeMasters; Denise M Damek
Journal:  J Neurooncol       Date:  2009-07-16       Impact factor: 4.130

5.  Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.

Authors:  M Birlik; S Akar; E Tuzel; F Onen; E Ozer; M Manisali; Z Kirkali; N Akkoc
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-27       Impact factor: 4.553

6.  Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein.

Authors:  Tamio Okimoto; Yukari Tsubata; Takamasa Hotta; Megumi Hamaguchi; Takae Okuno; Yohei Shiratsuki; Akari Kodama; Mika Nakao; Yoshihiro Amano; Shunichi Hamaguchi; Noriaki Kurimoto; Reiko Tobita; Takeshi Isobe
Journal:  Oncotarget       Date:  2018-04-13

7.  Gemcitabine-induced skin necrosis.

Authors:  Maria Monica Haydock; Saroj Sigdel; Toni Pacioles
Journal:  SAGE Open Med Case Rep       Date:  2018-10-30

8.  Gemcitabine-induced extensive skin necrosis.

Authors:  Sara D'epiro; Monica Salvi; Carlo Mattozzi; Simona Giancristoforo; Marco Campoli; Ramona Zanniello; Cecilia Luci; Laura Macaluso; Sara Giovannoni; Roberto Iacovelli; Stefano Calvieri; Antonio Giovanni Richetta
Journal:  Case Rep Med       Date:  2012-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.